All News

Clinicians will soon be able to treat patients with advanced Alzheimer?s disease (AD) using the first drug approved for use in the later stages of this progressive condition. The FDA recently approved memantine (Namenda, Forest Laboratories) for the treatment of moderate to severe AD. The drug will be available in pharmacies January.

What are PBMs worth today?

Author looks at the merger between Caremark and AdvancePCS and wonders if the purchase price makes sense

Clinicians will soon be able to offer HIV-positive patients a protease inhibitor (PI) that combines the convenience of flexible dosing with no restrictions on food or water. The FDA recently approved fosamprenavir (Lexiva, GlaxoSmithKline/Vertex Pharmaceuticals) for the treatment of HIV infection in adults in combination with other antiretroviral agents. Fosamprenavir will be available in pharmacies later this month.

Clinicians will soon be able to offer their patients the first aldosterone-receptor blocker to be approved for the treatment of congestive heart failure (CHF). The FDA recently approved eplerenone (Inspra, Pfizer) to improve the survival of stable patients with left ventricular systolic dysfunction and clinical evidence of CHF following an acute myocardial infarction (MI).

Pharmacy boards that licensed Medco mail order facilities are closely watching the federal lawsuit filed against the giant PBM that include allegations of numerous violations state pharmacy practice acts.

The federal prosecutor in Philadelphia filed fraud charges against Medco Health Solutions alledging that the PBM accepted drug manufacturer kickbacks for switching medications and ignored pharmacy practice regulations at its mail order facilites.

National Coordinating Council for Medication Error Reporting and Prevention issues guidelines to reduce med errors when meds are administered in schools, to the elderly in assisted living facilities, day care centers etc.

Clinicians will soon be able to treat serious bacterial infections using the first cyclic lipopeptide agent to receive FDA approval. The FDA recently approved daptomycin (Cubicin, Cubist Pharmaceuticals) for injection for the treatment of complicated skin and skin structure infections caused by susceptible strains of Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, S. agalactiae, S. dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-resistant strains only). Daptomycin is not indicated for the treatment of pneumonia. According to the manufacturer, daptomycin is expected to be available in hospitals in early November.

Several pharmacy groups plan to inform the Federal Trade Commission of their oppositon to the proposed merger of Caremark and AdvancePCS, two of the top four pharmacy benefit managers.